Phenotypic and Genotypic Characteristics of *Pseudomonas aeruginosa* Causing Bloodstream Infection from Six Tertiary Hospitals in Beijing, China

Yanning Ma¹, Jie Liu², Chunmei Bao³, Xiuhong Hao⁴, Jingui Cao⁵, Yan Wang⁶ and Jiyong Yang¹*

¹Center for Clinical Laboratory Medicine, Chinese PLA General Hospital, Beijing, China
²Department of Laboratory, PLA Army General Hospital, Beijing, China
³Clinical Diagnostic Center, 302nd Hospital of China, China
⁴Clinical Laboratory, Navy General Hospital, PLA, Beijing, China
⁵Department of Infection Control, Air Force General Hospital, PLA, Beijing, China
⁶Clinical Laboratory, Rocket Army General Hospital, PLA, Beijing, China

*Corresponding authors: Dr. Jiyong Yang, Center for Clinical Laboratory Medicine, Chinese PLA General Hospital, Beijing, 100853, China, Tel: +86-10-6693-6575, Fax: +86-10-6823-2198

Abstract

**Background:** *Pseudomonas aeruginosa* is one of the most prevalent pathogens in China. However, little is known about the prevalence of clinical *P. aeruginosa* isolates causing bloodstream infections (BSIs) in China.

**Methods:** BSI-causing *P. aeruginosa* (BSI-PA) was collected from six tertiary-care hospitals in Beijing. Genetic relatedness was analyzed by pulsed-field gel electrophoresis (PFGE); Antimicrobial susceptibility testing was performed by agar dilution method, and sequence types (STs) were evaluated by multilocus sequence typing (MLST).

**Results:** A total of 80 non-duplicated BSI-PA isolates were collected from December 2013 to December 2014 and categorized into 69 types (strains) using unique PFGE patterns. Among the 69 BSI-PA strains, 41 STs were identified. Overall, the primary STs were ST244, ST274, ST260 and ST1052 (n = 18), followed by ST270, ST235, ST1295 (n = 3), and ST242, ST275, ST316, ST357 (n = 2). There were 25 STs that only contained a single strain. Approximately 31.9% (22/69) of the strains exhibited carbapenem-resistant phenotype, and most of them carried *bla*<sub>VIM</sub>.

**Conclusion:** The majority of BSI-PA strains exhibited high genetic diversity and low resistance to commonly used antimicrobials.

**Keywords**

Molecular epidemiology; Antimicrobial susceptibilities; Bloodstream infections; *Pseudomonas aeruginosa*

Introduction

*Pseudomonas aeruginosa* is one of the most common causes of bloodstream infections (BSIs) in hospitalized patients. BSIs have been considered as a public health problem worldwide. For patients in the intensive care unit, BSIs are the leading healthcare-associated infections, and have been linked to high morbidity and mortality [1]. The mortality rate for *P. aeruginosa*-induced BSI has been found to be up to 42%, depending on the population studied [2].

The incidence of BSIs caused by multi-drug or pan-drug resistant pathogens is gradually increased in recent decades, it has attracted much attention from many researchers. Some studies revealed that the genetic background of *P. aeruginosa* is diverse, and the majority of BSI-PA isolates belong to non-clonal population [3].

Recently, 80 non-duplicate BSI-PA isolates were collected from six tertiary-care hospitals in Beijing from December 2013 to December 2014. Antimicrobial susceptibilities and prevalence of carbapenemase genes were detected. The molecular epidemiology was also analyzed.
Materials and Methods

**Bacterial isolates**

A retrospective multicentre study focusing on the prevalence of BSIs caused by Gram-negative pathogens was performed in six tertiary-care hospitals located in Beijing, China, including Chinese PLA General Hospital (Hospital A), 302nd Hospital of China (Hospital B), Rocket Army General Hospital, PLA (Hospital C), PLA Army General Hospital (Hospital D), Navy General Hospital, PLA (Hospital E) and Air Force General Hospital, PLA (Hospital F). A total of 80 non-duplicate clinical BSI-PA isolates were collected from December 2013 to December 2014. All clinical isolates were isolated by China-blue agar plate (Thermo Biochemical products [Beijing] Co., Ltd.) and identified by VITEK MS (bioMérieux SA, Marcy-l’Étoile, France). *P. aeruginosa* ATCC 27853 was used as the quality control strain for antimicrobial susceptibility testing. *Salmonella enterica* serovar Braenderup strain H9812 was used as a reference standard for pulsed-field gel electrophoresis (PFGE) using CHEF DR-III (Bio-Rad Laboratories). Interpretation of PFGE patterns was performed using the Dice similarity coefficient of BioNumerics software (Applied Maths, St-Martens-Latern, Belgium). Clusters were defined as DNA patterns based on ≥70% similarity. The strain with similarity <5% was considered as the representative of subtypes within the main group. No ethical approval was obtained for using the clinical samples as these samples were collected during routine bacteriological analyses in public hospitals and the data were analyzed anonymously.

**Antimicrobial susceptibility test**

Antimicrobial susceptibilities were determined by the agar dilution method. The following antibiotics were tested: piperacillin-tazobactam, ceftazidime, cefepime, cefoperazone-sulbactam, meropenem, imipenem, ciprofloxacin, aztreonam, amikacin. All susceptibility results were interpreted according to the performance standards of the Clinical and Laboratory Standards Institute (CLSI) [4].

**PFGE and MLST analyses**

PFGE with SpeI was performed for all clinical BSI-PA isolates. The PFGE patterns were analyzed by the Dice similarity coefficient of BioNumerics software (Applied Maths NV, Sint-Martens-Latem, Belgium). Isolates were considered as the same strain (PFGE type) if they possessed the genetic similarity of ≥95%. MLST was carried out for all strains according to the protocols available on the MLST websites (http://pubmlst.org/). STs were clustered into groups by eBURST v3.0 software (http://eburst.mlst.net/) to determine the clonal relationship among the isolates.

**Molecular detection of carbapenemase genes**

Carbapenemase genes, including **bla**₅₈, **bla**₉₈, **bla**₁₈₄, **bla**₂₄₄, **bla**₇₁₄, **bla**₁₇₉, **bla**₁₈₄, **bla**₂₄₄, **bla**₇₁₄, **bla**₁₇₉, **bla**₁₈₄, **bla**₂₄₄, **bla**₇₁₄, **bla**₁₇₉, and **bla**₂₄₄ were screened for carbapenem-non-susceptible BSI-PA strains as previously described [5].

**Results**

**Prevalence of BSI-PA.**

A total of 857 non-duplicate Gram-negative bacilli isolated from BSIs were collected from six tertiary-care hospitals in Beijing from December 2013 to December 2014. *P. aeruginosa* accounted for 9.3% (80/857) of all Gram-negative bacilli BSI episodes. Among 80 BSI-PA isolates, 19, 8, 16, 22, 10 and 5 isolates were obtained from hospitals A, B, C, D, E and F respectively.

**Genetic relatedness of BSI-PA**

Isolates with the same PFGE type were considered as the same strain. The 80 non-duplicate BSI-PA isolates were categorized into 69 types (strains) using unique PFGE patterns. Among them, 62 types only had one BSI-PA isolates, five types had 2 BSI-PA isolates, and two types contained four or three BSI-PA isolates, respectively. Therefore, a total of 69 BSI-PA strains without genetic relationship were further analyzed.

**MLST**

Among the 69 BSI-PA strains, 41 STs were identified. Overall, the primary STs were ST244, ST274, ST260 and ST1052 (n = 18), followed by ST270, ST235, ST1295 (n = 3), and ST242, ST275, ST316, ST357 (n = 2). Also, there were 25 STs that contain only a single strain.

**Antimicrobial susceptibility and prevalence of carbapenemase genes**

Approximately 76.3% and 72.5% of BSI-PA strains exhibited sensitive to meropenem and imipenem, respectively. While 76.3%, 54.4%, 91.3%, 86.5% and 71.3% of strains were sensitive to ceftazidime, cefepime amikacin, ciprofloxacin, aztreonam and piperacillin-tazobactam, respectively. Approximately 34.8% of the strains exhibited carbapenem-resistant phenotype. Most of them produced VIM carbapenemase (Table 1).

**Discussion**

*P. aeruginosa* is one of the leading causes of nosocomial infections and responsible for ~10% of all hospital-acquired infections worldwide [6]. In addition, *P. aeruginosa* is responsible for 15.6% of all nosocomial pneumonia cases in medical-surgical ICUs [7]. In China, *P. aeruginosa* accounts for 19.4% of all isolates in ventilator-associated pneumonia and exhibits a high level of resistance to commonly used clinical antibiotics [8]. In this study, *P. aeruginosa* was one of the most common pathogens for BSI and accounted for 9.3% of all Gram-negative bacilli BSI episodes. The susceptibility test showed that BSI-PA strains were highly sensitive to ceftazidime, amikacin and ciprofloxacin, which can be the choice for empiric anti-infective therapy.
Our results are similar to those of previous studies [9]. Therefore, it is necessary to raise the awareness of antimicrobial resistance associated with different *P. aeruginosa* strains because the resistance of *P. aeruginosa* isolated from different sites of infection or different regions to a given agent could be very diverse. The major mechanisms for the resistance of *P. aeruginosa* isolates to carbapenems include carbapenemase production, mutations may lead to low permeability of the bacteria outer membrane, and overexpression of efflux pumps [10]. In this study, 66.7% (16 of 24) of carbapenem-resistant strains produced VIM or IMP (Table 1), suggesting that carbapenemase production may play an important role in the carbapenem-resistant phenotype. Interestingly, 18.8% (13/69) of strains exhibited non-susceptible to carbapenem-resistant cephalosporin-susceptible phenotype (13/69) of strains exhibited non-susceptible to carbapenem-resistant cephalosporin-susceptible phenotype. For example, the imipenem-resistant ceftazidime-susceptible isolates showed decreased mRNA expression of oprD, and overexpression of mexB [12], while the loss of OprD and overexpression of mexXY-OprM and mexAB-OprM were associated with carbapenem resistance in cephalosporin-susceptible *P. aeruginosa* [13]. These results suggested that some mutations may result in decreased expression or absence of outer membrane proteins and overexpression of some efflux pumps target only certain carbapenems, and then lead to the carbapenem-resistant cephalosporin-susceptible phenotype in *P. aeruginosa* [10]. Thus, clinicians may consider the use of ceftazidime, cefepime, or piperacillin-tazobactam against these *P. aeruginosa* isolates. Some studies suggested that non-carbapenem-beta-lactams (ceftazidime, piperacillin, and/or piperacillin-tazobactam) may still be effective alternatives for short-course therapy for BSI caused by *P. aeruginosa* strains, but should be used with caution in high-inoculum infections such as endocarditis and osteomyelitis [11,12].

In this study, PFGE analysis showed that 89.9% (62/69) of clinical BSI-PA isolates had a unique pattern, indicating widespread diversification of BSI-PA strains in this area. The results from other regions also showed similar results [3,14]. The non-clonal population structure of BSI-PA isolates suggests that no clonal transmission of *P. aeruginosa* between inpatients with BSI, but these patients should be addressed even in

<table>
<thead>
<tr>
<th>No.</th>
<th>ST</th>
<th>Carbapenemases</th>
<th>Minimum inhibitory concentrations (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>CAZ</td>
</tr>
<tr>
<td>P301001</td>
<td>1295</td>
<td>Undetected</td>
<td>64</td>
</tr>
<tr>
<td>P301002</td>
<td>316</td>
<td>VIM</td>
<td>2</td>
</tr>
<tr>
<td>P301003</td>
<td>270</td>
<td>Undetected</td>
<td>32</td>
</tr>
<tr>
<td>P301005</td>
<td>274</td>
<td>VIM</td>
<td>8</td>
</tr>
<tr>
<td>P301009</td>
<td>274</td>
<td>Undetected</td>
<td>32</td>
</tr>
<tr>
<td>P301111</td>
<td>316</td>
<td>IMP</td>
<td>&gt; 64</td>
</tr>
<tr>
<td>P301102</td>
<td>664</td>
<td>VIM</td>
<td>4</td>
</tr>
<tr>
<td>P301103</td>
<td>1453</td>
<td>VIM</td>
<td>8</td>
</tr>
<tr>
<td>P302004</td>
<td>242</td>
<td>VIM</td>
<td>&gt; 64</td>
</tr>
<tr>
<td>P302007</td>
<td>560</td>
<td>VIM</td>
<td>4</td>
</tr>
<tr>
<td>P303004</td>
<td>235</td>
<td>VIM</td>
<td>32</td>
</tr>
<tr>
<td>P303009</td>
<td>828</td>
<td>VIM</td>
<td>8</td>
</tr>
<tr>
<td>P303015</td>
<td>205</td>
<td>Undetected</td>
<td>32</td>
</tr>
<tr>
<td>P303016</td>
<td>OTHER</td>
<td>IMP</td>
<td>32</td>
</tr>
<tr>
<td>P303017</td>
<td>235</td>
<td>IMP</td>
<td>8</td>
</tr>
<tr>
<td>P303001</td>
<td>498</td>
<td>VIM</td>
<td>4</td>
</tr>
<tr>
<td>P303007</td>
<td>270</td>
<td>VIM</td>
<td>2</td>
</tr>
<tr>
<td>P303008</td>
<td>OTHER</td>
<td>Undetected</td>
<td>32</td>
</tr>
<tr>
<td>P303009</td>
<td>260</td>
<td>Undetected</td>
<td>2</td>
</tr>
<tr>
<td>P303010</td>
<td>260</td>
<td>Undetected</td>
<td>2</td>
</tr>
<tr>
<td>P303016</td>
<td>971</td>
<td>VIM</td>
<td>32</td>
</tr>
<tr>
<td>P311002</td>
<td>244</td>
<td>Undetected</td>
<td>8</td>
</tr>
<tr>
<td>P311003</td>
<td>OTHER</td>
<td>VIM</td>
<td>8</td>
</tr>
<tr>
<td>P311005</td>
<td>267</td>
<td>DIM</td>
<td>64</td>
</tr>
</tbody>
</table>

ST: Sequence Type; OTHER: Novel STs that do not exist in the MLST databases of *P. aeruginosa*; CAZ: Ceftazidime; CFP: Cefoperazone; FEP: Cefepime; SCF: Cefoperazone/Sulbactam; TZP: Piperacillin/Tazobactam; IPM: Imipenem; MEM: Meropenem; AMK: Amikacin; CIP: Ciprofloxacin; LEV: Levofloxacin; ATM: Aztreonam; MH: Minocycline.
Figure 1: The eBURST diagram of MLST. Lines connect single locus variants. The relative size of the dots indicates the abundance of each ST.

the non-outbreak setting. The results also indicate the importance of continuous, consistent surveillance of nosocomial infections in high-risk patients. In addition, the MLST results of BSI-PA showed a genetic background of clone diversity distribution, but no significant clone prevalence (Figure 1). Other studies have reported that the genetic background of *P. aeruginosa* is diverse [15], which is consistent with the results in this study. Only two small outbreaks of BSI-PA strains occurred, in which ST1052 and ST274 appeared in four and five BSI-PA strains, respectively.

However, the present study has the following limitations. First, the main drawback of the study is the paucity of information on the clinical characterization of patients. Second, the resistance mechanisms other than MBL production, such as the expression of OprD and MexAB-OprM have not been analyzed.

**Acknowledgement**

This study was financially supported by the Special Key Project of Biosafety Technologies for the National Major Research & Development Program of China (2017YFC1200803).

**Transparency Declaration**

The authors have no conflicts of interest to declare.

**References**

4. CLSI (2017) Performance Standards for Antimicrobial Susceptibility Testing. (27th edn), Clinical and Laboratory Standards Institute, M100, USA.


against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis 75: 412-416.

